Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

IRadimed Corporation (IRMD)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
38.29-0.90 (-2.30%)
At close: 04:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close39.19
Open39.50
Bid34.00 x 800
Ask38.51 x 800
Day's Range37.68 - 39.79
52 Week Range21.65 - 45.01
Volume36,148
Avg. Volume36,945
Market Cap471.446M
Beta (5Y Monthly)1.05
PE Ratio (TTM)472.72
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    IRADIMED CORPORATION Announces Third Quarter 2021 Financial Results

    Reports third quarter 2021 revenue of $10.9 million, GAAP diluted EPS of $0.20 and non-GAAP diluted EPS of $0.23Increases full-year 2021 financial guidance WINTER SPRINGS, Fla., Oct. 29, 2021 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems

  • GlobeNewswire

    IRADIMED CORPORATION to Hold 2021 Third Quarter Financial Results Conference Call on October 29th

    WINTER SPRINGS, Fla., Oct. 08, 2021 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2021 third quarter financial results before the market opens on Friday, October 29th. IRADIMED management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in listening to the conference call may do so by dialing 1-844-413-1781 for domestic callers, or 1-71

  • GlobeNewswire

    IRADIMED CORPORATION Announces Second Quarter 2021 Financial Results

    Reports second quarter 2021 revenue of $9.8 million, GAAP diluted EPS of $0.12 and non-GAAP diluted EPS of $0.14Issues Q3 and full year 2021 financial guidance WINTER SPRINGS, Fla., July 30, 2021 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring sys

Advertisement
Advertisement